Estados Unidos · Plataformas y datos · MarketBeat

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 7% After Analyst Downgrade

Publicado por MarketBeat · Estados Unidos hace 1 h

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 7% on Analyst Downgrade

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

También te puede interesar

Marriott projects 2027 global RevPAR growth of 3.5%-4.5% while raising 2026 outlook to 4.5%-5%

41% of Americans expect to be poorer next year. Here’s what that means for Bitcoin

Greystone Logistics Director Larry LeBarre Retires from Board

Budget, debt ceiling negotiations on deck as midterms could create divided federal government

Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations

Magna Earnings: Restructuring Bearing Fruit With Strong Third Quarter